PF-Atlas › Treatments › Galectin-3 Inhibition
Galectin-3 Inhibition
Inhaled galectin-3 inhibitor blocks fibroblast activation and TGF-β release
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase II
Evidence level
Level 2 (Phase II)
Mechanism class
Inhaled galectin-3 inhibitor blocks fibroblast activation and TGF-β release
Timeline
2-3 years
Risk profile
Low
Developer
Galecto Biotech
Key researchers
Multiple
Overview
Inhaled delivery directly to lung. Galectin-3 is elevated in IPF BAL fluid and drives macrophage-to-myofibroblast activation. Phase IIb results pending.
How Galectin-3 Inhibition fits into IPF treatment
Galectin-3 Inhibition is classified as Level 2 (Phase II) at the Phase II stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Galectin-3 Inhibition for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.